Literature DB >> 16584444

Preparation of soluble infectious samples from scrapie-infected brain: a new tool to study the clearance of transmissible spongiform encephalopathy agents during plasma fractionation.

Vito Angelo Berardi1, Franco Cardone, Angelina Valanzano, Mei Lu, Maurizio Pocchiari.   

Abstract

BACKGROUND: Concern about the safety of blood, blood components, and plasma-derived products with respect to prions has increased since the report of two blood-related infections of variant Creutzfeldt-Jakob disease in the United Kingdom. Efforts were directed toward the development of procedures able to remove or inactivate prions from blood components or plasma-derived products with brain fractions of transmissible spongiform encephalopathy (TSE)-infected rodents as spiking materials. These spiking materials, however, are loaded with pathological prion protein (PrP(TSE)) aggregates that are likely not associated to blood infectivity. The presence of these aggregates may invalidate these studies. STUDY DESIGN AND METHODS: Brains from 263K scrapie-infected hamsters were suspended in 10 percent phosphate-buffered saline. After low-speed centrifugation, the supernatant was collected and ultracentrifuged at 220,000 x g at 25 degrees C for 30 minutes. The high-speed supernatants (S(HS)) and pellets were collected; the proteinase-resistant PrP(TSE) was measured by Western blot and infectivity by intracerebral inoculation into weanling hamsters.
RESULTS: A substantial amount of prion infectivity (more than 10(5) LD(50) per mL of a 10% suspension of brain tissues) is present in the S(HS) fraction of 263K scrapie-infected hamster brains. Concomitantly, this fraction contains none or only traces of PrP(TSE) in its aggregate form.
CONCLUSION: This study describes a simple and fast protocol to prepare infectious material from 263K scrapie-infected brains that is not contaminated with PrP(TSE) aggregates. This S(HS) fraction is likely to be the most relevant material for endogenous spiking of human blood in validation experiments aimed at demonstrating procedures to remove or inactivate TSE infectious agents.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16584444     DOI: 10.1111/j.1537-2995.2006.00763.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  10 in total

1.  Report of the Working Group 'Overall Blood Supply Strategy with Regard to Variant Creutzfeldt-Jakob Disease (vCJD)': Statement on the Development and Implementation of Test Systems Suitable for the Screening of Blood Donors for vCJD - Dated September 17, 2008.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

2.  Pathogenic mutations within the hydrophobic domain of the prion protein lead to the formation of protease-sensitive prion species with increased lethality.

Authors:  Bradley M Coleman; Christopher F Harrison; Belinda Guo; Colin L Masters; Kevin J Barnham; Victoria A Lawson; Andrew F Hill
Journal:  J Virol       Date:  2013-12-18       Impact factor: 5.103

3.  Recovery of small infectious PrP(res) aggregates from prion-infected cultured cells.

Authors:  Zaira E Arellano Anaya; Jimmy Savistchenko; Véronique Massonneau; Caroline Lacroux; Olivier Andréoletti; Didier Vilette
Journal:  J Biol Chem       Date:  2011-01-06       Impact factor: 5.157

4.  Transmission of Soluble and Insoluble α-Synuclein to Mice.

Authors:  Daryl Rhys Jones; Marion Delenclos; AnnMarie T Baine; Michael DeTure; Melissa E Murray; Dennis W Dickson; Pamela J McLean
Journal:  J Neuropathol Exp Neurol       Date:  2015-12       Impact factor: 3.685

5.  The physical relationship between infectivity and prion protein aggregates is strain-dependent.

Authors:  Philippe Tixador; Laëtitia Herzog; Fabienne Reine; Emilie Jaumain; Jérôme Chapuis; Annick Le Dur; Hubert Laude; Vincent Béringue
Journal:  PLoS Pathog       Date:  2010-04-15       Impact factor: 6.823

Review 6.  Recent advances in prion chemotherapeutics.

Authors:  Valerie L Sim; Byron Caughey
Journal:  Infect Disord Drug Targets       Date:  2009-02

7.  Unexpected prion phenotypes in experimentally transfused animals: predictive models for humans?

Authors:  Emmanuel E Comoy; Jacqueline Mikol; Jean-Philippe Deslys
Journal:  Prion       Date:  2018-08-16       Impact factor: 3.931

8.  Experimental transfusion of variant CJD-infected blood reveals previously uncharacterised prion disorder in mice and macaque.

Authors:  Emmanuel E Comoy; Jacqueline Mikol; Nina Jaffré; Vincent Lebon; Etienne Levavasseur; Nathalie Streichenberger; Chryslain Sumian; Armand Perret-Liaudet; Marc Eloit; Olivier Andreoletti; Stéphane Haïk; Philippe Hantraye; Jean-Philippe Deslys
Journal:  Nat Commun       Date:  2017-11-02       Impact factor: 14.919

9.  Quaternary structure of pathological prion protein as a determining factor of strain-specific prion replication dynamics.

Authors:  Florent Laferrière; Philippe Tixador; Mohammed Moudjou; Jérôme Chapuis; Pierre Sibille; Laetitia Herzog; Fabienne Reine; Emilie Jaumain; Hubert Laude; Human Rezaei; Vincent Béringue
Journal:  PLoS Pathog       Date:  2013-10-10       Impact factor: 6.823

10.  Enzymatic formulation capable of degrading scrapie prion under mild digestion conditions.

Authors:  Emeka A Okoroma; Diane Purchase; Hemda Garelick; Roger Morris; Michael H Neale; Otto Windl; Oduola O Abiola
Journal:  PLoS One       Date:  2013-07-16       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.